Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer
Cancer Medicine · 2026-07 · 15 (7)
DOI: 10.1002/cam4.72072 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 01.07.2026. Verfasst von Kunihiro Odagiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions, Eosinophils. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Patientensicherheit
Abstract (Originalsprache)
There is an unmet need to predict immune‐related adverse events (irAEs) in patients receiving immune checkpoint inhibitors. This study aimed to examine whether eosinophils can predict irAEs in metastatic urothelial carcinoma (mUC). In this multicenter cohort study, we retrospectively examined eosinophil before (baseline sample) and 3 weeks after treatment (3‐week sample) in 124 patients with mUC treated with pembrolizumab between January 2018 and October 2024. We divided the patients into two groups depending on whether they had experienced an irAE (irAE group) or not (non‐irAE group). The variation in eosinophil proportion from baseline to 3 weeks was significantly higher in the irAE group than in the non‐irAE group (non‐irAE, 2.4%–3.1%; irAE, 2.2%–4.3%; p < 0.05). Notably, the variation in eosinophils from baseline to 3 weeks in patients with bladder cancer was significantly higher in the irAE group than in the non‐irAE group (non‐irAE, 2.5%–2.8%; irAE, 1.9%–4.1%; p < 0.05), but not in upper urinary tract urothelial cancer (non‐irAE, 2.2%–3.7%; irAE, 2.8%–4.4%; p = 0.97). The optimal cutoff value for eosinophils in patients with bladder cancer against the occurrence of any‐grade irAEs was 5.0% (area under the curve = 0.655). Multivariable analyses showed that eosinophil levels ≥ 5.0% increased the risk of any‐grade irAEs in patients with bladder cancer (odds ratio 3.61, 95% confidence interval, 1.00–13.0). An eosinophil proportion ≥ 5.0% may be an effective biomarker for evaluating pembrolizumab‐induced irAEs in patients with mUC, particularly those with bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Urology, Nagoya City University West Medical Center, Nagoya, Japan.
- Department of Urology, Anjo Kosei Hospital, Anjo, Japan.
- Department of Urology, Konan Kosei Hospital, Konan, Japan.
ORCID-Profile: Taku Naiki, Toshiharu Morikawa, Yoshihisa Mimura, Yosuke Sugiyama, Noriyasu Kawai, Yoko Furukawa-Hibi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Odagiri, K., Tasaki, Y., Naiki, T., Morikawa, T., Iida, K., Noda, Y., Banno, R., Isobe, T., Shimizu, N., Aoki, M., Mimura, Y., Sugiyama, Y., Nagai, T., Etani, T., Hamamoto, S., Ando, R., Kawai, N., Furukawa-Hibi, Y., & Yasui, T. (2026). Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72072
Vancouver
Odagiri K, Tasaki Y, Naiki T, Morikawa T, Iida K, Noda Y, et al. Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72072
BibTeX
@article{Odagiri2026,
author = {Odagiri, Kunihiro and Tasaki, Yoshihiko and Naiki, Taku and Morikawa, Toshiharu and Iida, Keitaro and Noda, Yusuke and Banno, Rika and Isobe, Teruki and Shimizu, Nobuhiko and Aoki, Maria and Mimura, Yoshihisa and Sugiyama, Yosuke and Nagai, Takashi and Etani, Toshiki and Hamamoto, Shuzo and Ando, Ryosuke and Kawai, Noriyasu and Furukawa-Hibi, Yoko and Yasui, Takahiro},
title = {Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cam4.72072}
}
EUVIMED